Washington, D.C. 20549


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2021
OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
(Commission File Number)(I.R.S. Employer Identification Number)
2850 Frontier Drive
Warsaw, Indiana
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00025 par value per shareKIDSNasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 2.02. Results of Operations and Financial Condition.

On October 13, 2021, OrthoPediatrics Corp. (the "Company”) issued a press release announcing its preliminary unaudited revenue for the third quarter ended September 30, 2021 and providing a related business update. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The Company's preliminary quarterly revenue estimate included in this Form 8-K is subject to the completion of certain audit and review procedures, which may result in adjustments being reflected in our actual results. The Company has also reiterated its 2021 total revenue guidance in this Form 8-K. The Company’s actual results for the quarter ended September 30, 2021 and total revenues for the year ended December 31, 2021 could differ materially from the estimates provided in this Form 8-K. You should refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2021, as updated and supplemented by our other SEC reports filed from time to time, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, you are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

* * * * * *


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OrthoPediatrics Corp.
Date:   October 13, 2021By:/s/ Daniel J. Gerritzen
Daniel J. Gerritzen,
General Counsel and Secretary

- 2 -
  OrthoPediatrics Corp. Announces Preliminary Unaudited Revenue for the Third Quarter 2021 and  Reiterates 2021 Revenue Guidance     WARSAW, Indiana, October 13, 2021— OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”)  (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today  announced preliminary revenue for the third quarter ended September 30, 2021 and provided a related  business update.    Preliminary unaudited third quarter 2021 revenue is expected to be approximately $25.1 million, up  13% when compared to revenue of $22.2 million in the third quarter 2020.  The third quarter 2021  revenue was impacted by increased COVID‐19 Delta cases as well as respiratory syncytial virus (RSV)  cases within the children’s hospitals combined with hospital staff shortages.  Despite this impact, the  Company reiterates its 2021 total revenue guidance range of $97 to $101 million. The preliminary  quarterly revenue estimate for 2021 included in this press release is prior to the completion of review  and audit procedures by the Company’s independent registered public accounting firm and therefore  subject to adjustments.    OrthoPediatrics will host a conference call on Thursday, November 4, 2021, at 8:00 a.m. ET to discuss  the results. The dial‐in numbers are (855) 289‐4603 for domestic callers and (614) 999‐9389 for  international callers. The conference ID number is 8161847. A live webcast of the conference call will be  available online from the investor relations page of the OrthoPediatrics’ corporate website at    Forward‐Looking Statements  This press release includes "forward‐looking statements" within the meaning of U.S. federal securities  laws, including the statements regarding OrthoPediatrics’ preliminary revenue for the third quarter  ended September 30, 2021, and other statements identified by the use of words such as "may," "might,"  "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target,"  "predict," "intend," "future," "goals," "potential," "objective," "would" and other similar expressions.  Forward‐looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics’  control. Important factors could cause actual results to differ materially from those in the forward‐ looking statements, including, among others: the risks related to COVID‐19, the continued impact such  pandemic may have on the demand for our products, and our ability to respond to the related  challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’  Annual Report on Form 10‐K filed with the Securities and Exchange Commission (the "SEC") on March  11, 2021 as updated and supplemented by our other SEC reports filed from time to time. Forward‐ looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to  update forward‐looking statements to reflect actual results, subsequent events, or circumstances or  other changes affecting such statements except to the extent required by applicable securities laws.    About OrthoPediatrics Corp.  Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of  pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric  orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently  markets 36 surgical systems  that serve  three of  the  largest categories within  the pediatric orthopedic 

market.  This  product  offering  spans  trauma  and  deformity,  scoliosis,  and  sports  medicine/other  procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and  distributes  its  products  in  the  United  States  and  45  countries  outside  the  United  States.  For more  information, please visit    Investor Contact  Gilmartin Group  Matt Bacso, CFA